Ulhas Dhuppad

Mr. Ulhas Dhuppad is the President and head of Global Pharmaceutical Development at Glenmark. He is responsible for driving generics research, specialty formulations, global regulatory affairs, and project management. He brings with him rich experience spanning more than three decades. In this duration, he has developed more than 300 products including complex generics for USA and Europe and many specialty products for emerging markets. Ulhas has been instrumental in designing development strategies and successfully filing niche products and has expertise in development of complex dosage forms. His areas of focus include setting of systems for robust and in time product development.

Mr. Dhuppad has worked in leading pharmaceutical companies like Cadila Laboratories, Cipla, Lupin, and Morepen Laboratories. He has been previously associated with Glenmark for 15 years leading CMC development, and during this period was a key contributor in building the Global Formulations R&D function. More recently, he was President – R&D at Alkem Laboratories.

Mr. Dhuppad holds a Master’s Degree in Pharmacy from Pune University.